Michał Janiak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Michał Janiak has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Lidia Wydeheft
Department of Geriatrics, Faculty of Health Sciences, L. Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Skłodowskiej Curie 9 Str., 85-094 Bydgoszcz, Poland
3 shared publications - Kornelia Kędziora-Kornatowska
Department of Geriatrics, Faculty of Health Science, L. Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Skłodowska-Curie 9 Street, 85-094 Bydgoszcz, Poland
2 shared publications - Aleksandra Wijata
Department of Cardiology and Clinical Pharmacology, Faculty of Health Sciences, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, 87-100 Toruń, Poland
1 shared publication - Anna Bych
Biziel University Hospital in Bydgoszcz, Poland
1 shared publication - Dorota Ratajczak
Department of Geriatrics, Faculty of Health Science, L. Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Bydgoszcz, Poland
1 shared publication - Grzegorz Grześk
Department of Cardiology and Clinical Pharmacology, Faculty of Health Sciences, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Bydgoszcz, Poland
1 shared publication
Latest Publications
- Open Access
- 31 December 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 48
Providing general anesthesia for elderly patients during planned procedures — main differences compared to younger adults
IntroductionThe aging population has increased the number of older adults undergoing elective surgery, making safe, individualized general anesthesia essential. Age-related physiological changes—such as reduced cardiac, pulmonary, hepatic, and renal reserve, multimorbidity, frailty, and altered body composition—affect drug metabolism, pharmacodynamics, and tolerance to perioperative stress, resulting in higher rates of cardiovascular, respiratory, and cognitive complications compared with younger adults.ResultsOlder patients require careful dose adjustments due to reduced drug clearance and increased sensitivity to anesthetics. Propofol-based total intravenous anesthesia (TIVA), EEG-guided depth monitoring, and agents like etomidate or dexmedetomidine improve hemodynamic stability and reduce postoperative cognitive dysfunction (POCD) and delirium. Comprehensive preoperative evaluation—including frailty screening, cognitive and functional assessment, and medication review—helps identify high-risk patients. Postoperative vigilance is needed to manage respiratory depression, inadequate pain control, and prolonged recovery. Telemedicine has proven effective for pre-anesthetic assessment, enabling early detection of cognitive impairment and reducing time, cost, and travel burden.DiscussionPersonalized anesthesia considering frailty, comorbidities, and altered drug metabolism improves safety. Minimizing anesthetic duration, selecting safer agents, EEG guidance, and TIVA support better outcomes, while telemedicine enhances patient-centered care.ConclusionGeneral anesthesia in older adults requires tailored strategies addressing age-related changes and increased perioperative vulnerability. Individualized dosing, careful agent selection, structured preoperative assessment, postoperative monitoring, and telemedicine support can enhance safety and outcomes, highlighting key differences from younger patients and emphasizing a holistic, evidence-based perioperative approach.
- 31 December 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 48
Open AccessProviding general anesthesia for elderly patients during planned procedures — main differences compared to younger adults
IntroductionThe aging population has increased the number of older adults undergoing elective surgery, making safe, individualized general anesthesia essential. Age-related physiological changes—such as reduced cardiac, pulmonary, hepatic, and renal reserve, multimorbidity, frailty, and altered body composition—affect drug metabolism, pharmacodynamics, and tolerance to perioperative stress, resulting in higher rates of cardiovascular, respiratory, and cognitive complications compared with younger adults.ResultsOlder patients require careful dose adjustments due to reduced drug clearance and increased sensitivity to anesthetics. Propofol-based total intravenous anesthesia (TIVA), EEG-guided depth monitoring, and agents like etomidate or dexmedetomidine improve hemodynamic stability and reduce postoperative cognitive dysfunction (POCD) and delirium. Comprehensive preoperative evaluation—including frailty screening, cognitive and functional assessment, and medication review—helps identify high-risk patients. Postoperative vigilance is needed to manage respiratory depression, inadequate pain control, and prolonged recovery. Telemedicine has proven effective for pre-anesthetic assessment, enabling early detection of cognitive impairment and reducing time, cost, and travel burden.DiscussionPersonalized anesthesia considering frailty, comorbidities, and altered drug metabolism improves safety. Minimizing anesthetic duration, selecting safer agents, EEG guidance, and TIVA support better outcomes, while telemedicine enhances patient-centered care.ConclusionGeneral anesthesia in older adults requires tailored strategies addressing age-related changes and increased perioperative vulnerability. Individualized dosing, careful agent selection, structured preoperative assessment, postoperative monitoring, and telemedicine support can enhance safety and outcomes, highlighting key differences from younger patients and emphasizing a holistic, evidence-based perioperative approach.
- Open Access
- 28 September 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 68, 55416
Bempedoic Acid: A Novel Approach in Managing Dyslipidemia and Reducing Cardiovascular Risk
Cardiovascular disease remains one of the leading causes of mortality worldwide, with elevated LDL cholesterol being a critical risk factor. Statins have long been the cornerstone of lipid-lowering therapy, but many patients fail to reach target LDL cholesterol levels due to statin intolerance or insufficient response, even when combined with ezetimibe. Recently, the lipid-lowering drug class has been expanded with the introduction of bempedoic acid, a novel agent that inhibits ATP-citrate lyase. Recent studies have demonstrated the efficacy and safety of bempedoic acid in reducing LDL cholesterol levels in patients with hypercholesterolemia, paving the way for its inclusion in clinical guidelines. This article provides a comprehensive overview of the latest evidence regarding bempedoic acid and its emerging role in lipid management. Despite the widespread use of statins, many patients fail to achieve target LDL-C levels due to statin intolerance or insufficient response. This comprehensive review explores the emerging role of bempedoic acid, a novel lipid-lowering agent that inhibits ATP-citrate lyase, in the management of dyslipidemia and cardiovascular risk reduction. Bempedoic acid, approved by the FDA in 2020, offers a unique mechanism of action that complements existing therapies. As a prodrug activated specifically in the liver, it avoids muscle-related side effects commonly associated with statins. Clinical trials have demonstrated its efficacy in reducing LDL-C levels, particularly in patients with statin intolerance or those requiring additional LDL-C lowering beyond maximally tolerated statin therapy. The review synthesizes data from multiple phase 3 clinical trials, including CLEAR Wisdom and CLEAR Outcomes, which have shown significant LDL-C reductions with bempedoic acid monotherapy and in combination with other lipid-lowering agents. Notably, bempedoic acid not only lowers LDL-C but also reduces high-sensitivity C-reactive protein (hs-CRP) levels, suggesting potential anti-inflammatory effects. Safety profiles from these trials indicate that bempedoic acid is generally well-tolerated, with minimal muscle-related adverse events. However, slight increases in serum creatinine and uric acid levels have been observed, warranting monitoring in certain patient populations. Recent updates to clinical guidelines, including the 2024 European Society of Cardiology guidelines on coronary heart disease, now recommend bempedoic acid for specific patient groups. These include statin-intolerant patients not achieving LDL-C goals on ezetimibe alone, and those not reaching targets on maximum tolerated statin doses combined with ezetimibe. This review concludes that bempedoic acid represents a significant advancement in lipid-lowering therapy, offering a valuable option for patients with hypercholesterolemia, particularly those with statin intolerance or requiring additional LDL-C reduction. As research continues, bempedoic acid's role in reducing cardiovascular events and its long-term safety profile will be further elucidated, potentially reshaping the landscape of dyslipidemia management and cardiovascular risk reduction.
- 28 September 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 68, 55416
Open AccessBempedoic Acid: A Novel Approach in Managing Dyslipidemia and Reducing Cardiovascular Risk
Cardiovascular disease remains one of the leading causes of mortality worldwide, with elevated LDL cholesterol being a critical risk factor. Statins have long been the cornerstone of lipid-lowering therapy, but many patients fail to reach target LDL cholesterol levels due to statin intolerance or insufficient response, even when combined with ezetimibe. Recently, the lipid-lowering drug class has been expanded with the introduction of bempedoic acid, a novel agent that inhibits ATP-citrate lyase. Recent studies have demonstrated the efficacy and safety of bempedoic acid in reducing LDL cholesterol levels in patients with hypercholesterolemia, paving the way for its inclusion in clinical guidelines. This article provides a comprehensive overview of the latest evidence regarding bempedoic acid and its emerging role in lipid management. Despite the widespread use of statins, many patients fail to achieve target LDL-C levels due to statin intolerance or insufficient response. This comprehensive review explores the emerging role of bempedoic acid, a novel lipid-lowering agent that inhibits ATP-citrate lyase, in the management of dyslipidemia and cardiovascular risk reduction. Bempedoic acid, approved by the FDA in 2020, offers a unique mechanism of action that complements existing therapies. As a prodrug activated specifically in the liver, it avoids muscle-related side effects commonly associated with statins. Clinical trials have demonstrated its efficacy in reducing LDL-C levels, particularly in patients with statin intolerance or those requiring additional LDL-C lowering beyond maximally tolerated statin therapy. The review synthesizes data from multiple phase 3 clinical trials, including CLEAR Wisdom and CLEAR Outcomes, which have shown significant LDL-C reductions with bempedoic acid monotherapy and in combination with other lipid-lowering agents. Notably, bempedoic acid not only lowers LDL-C but also reduces high-sensitivity C-reactive protein (hs-CRP) levels, suggesting potential anti-inflammatory effects. Safety profiles from these trials indicate that bempedoic acid is generally well-tolerated, with minimal muscle-related adverse events. However, slight increases in serum creatinine and uric acid levels have been observed, warranting monitoring in certain patient populations. Recent updates to clinical guidelines, including the 2024 European Society of Cardiology guidelines on coronary heart disease, now recommend bempedoic acid for specific patient groups. These include statin-intolerant patients not achieving LDL-C goals on ezetimibe alone, and those not reaching targets on maximum tolerated statin doses combined with ezetimibe. This review concludes that bempedoic acid represents a significant advancement in lipid-lowering therapy, offering a valuable option for patients with hypercholesterolemia, particularly those with statin intolerance or requiring additional LDL-C reduction. As research continues, bempedoic acid's role in reducing cardiovascular events and its long-term safety profile will be further elucidated, potentially reshaping the landscape of dyslipidemia management and cardiovascular risk reduction.
- Open Access
- 12 October 2022
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 12 (11) , 183-191
Clinical significancy of WNT pathway inhibition in various cancers
The tumor microenvironment (TME) plays an important role in the cell cycle. There is a correlation between the Wnt/B–catenin signaling pathway and TME. This article reviews methods of inhibiting Wnt Pathway, a useful process in the treatment of various cancers. Compounds of Wnt/β–Catenin Signaling Pathway, such as TCF–1, have an impact on the differentiation and migration of CD8+ T cells. CCL4 expression is regulated by the beta–catenin protein to recruit CD103+ dendritic cells, which enables CD8+ T cell activation. Inhibition of the Wnt/β–catenin pathway has an impact on ovarian cancer patients’ prognosis, reducing the development of ovarian cancer. Research shows that inhibition of the pathway with the use of the LGK974 inhibitor may boost immunity, especially when applied with a Paclitaxel mix. After treatment, expression of the inhibitory receptors CTLA–4, TIM3, PD–1 on CD8+ T cells decreased. The combination of LGK974 and Paclitaxel can cause the death of tumor cells and significantly inhibit their proliferation. The application of dose–dense Paclitaxel avoids toxicity related to the maximum dose needed to protect the patient's immune system by increasing CD8+ TILs. There are concerns regarding toxicity of the LGK 974, especially for cells dependent on the Wnt/β–catenin pathway to maintain homeostasis. Many Wnt/β–catenin pathway inhibitors are tested against colorectal cancer (CRC) with successful results. These include NSAIDs, porcupine inhibitors, tankyrase inhibitors, Wnt5A inhibitors, and disheveled protein inhibitors.The Wnt/β–catenin pathway, when expressed in Triple Negative Breast Cancer (TNBC), leads to the transition of epithelial to mesenchymal cells. In early clinical development, there are multiple inhibitors (ex. KYA1797K) targeting the Wnt/β–catenin pathway in TNBC cells, which could become a viable anticancer strategy.
- 12 October 2022
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 12 (11) , 183-191
Open AccessClinical significancy of WNT pathway inhibition in various cancers
The tumor microenvironment (TME) plays an important role in the cell cycle. There is a correlation between the Wnt/B–catenin signaling pathway and TME. This article reviews methods of inhibiting Wnt Pathway, a useful process in the treatment of various cancers. Compounds of Wnt/β–Catenin Signaling Pathway, such as TCF–1, have an impact on the differentiation and migration of CD8+ T cells. CCL4 expression is regulated by the beta–catenin protein to recruit CD103+ dendritic cells, which enables CD8+ T cell activation. Inhibition of the Wnt/β–catenin pathway has an impact on ovarian cancer patients’ prognosis, reducing the development of ovarian cancer. Research shows that inhibition of the pathway with the use of the LGK974 inhibitor may boost immunity, especially when applied with a Paclitaxel mix. After treatment, expression of the inhibitory receptors CTLA–4, TIM3, PD–1 on CD8+ T cells decreased. The combination of LGK974 and Paclitaxel can cause the death of tumor cells and significantly inhibit their proliferation. The application of dose–dense Paclitaxel avoids toxicity related to the maximum dose needed to protect the patient's immune system by increasing CD8+ TILs. There are concerns regarding toxicity of the LGK 974, especially for cells dependent on the Wnt/β–catenin pathway to maintain homeostasis. Many Wnt/β–catenin pathway inhibitors are tested against colorectal cancer (CRC) with successful results. These include NSAIDs, porcupine inhibitors, tankyrase inhibitors, Wnt5A inhibitors, and disheveled protein inhibitors.The Wnt/β–catenin pathway, when expressed in Triple Negative Breast Cancer (TNBC), leads to the transition of epithelial to mesenchymal cells. In early clinical development, there are multiple inhibitors (ex. KYA1797K) targeting the Wnt/β–catenin pathway in TNBC cells, which could become a viable anticancer strategy.
- Open Access
- 26 April 2022
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 12 (6) , 39-50
The effect of obstructive sleep apnea on the cardiovascular system
Introduction: Obstructive Sleep Apnea is a disease entity that affects many aspects of life, but is often overlooked and underdiagnosed. OSA is defined as episodes of apnea-hypopnea that disturbs not only sleep, but also daytime functioning. Symptoms can be divided into night symptoms (not breathing, snoring, gasping, fragmented sleep) and daytime symptoms (fatigue, low concentration, morning headaches, decreased libido). Moreover, OSA through many mechanisms affects the cardiovascular system and leads to its dysfunction. Purpose: The aim of this study is to draw attention to the often underdiagnosed disease entity, which is OSA, which, if left untreated, may lead to serious complications. Material and methods: In 2022, the PubMed and Google Scholar databases were searched using the following keywords: OSA, apnea, cardiovascular disorders, arrhythmias and heart disease. Works in English with the most recent data have been selected. Summary: OSA is strongly associated with cardiovascular disorders, moreover, in both cases, we find similar risk factors for these disorders. A correlation has been demonstrated between OSA and atrial fibrillation, hypertension, and arrhythmias. On the other hand, OSA is still underdiagnosed and more research is needed to understand the correlation between these diseases.
- 26 April 2022
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 12 (6) , 39-50
Open AccessThe effect of obstructive sleep apnea on the cardiovascular system
Introduction: Obstructive Sleep Apnea is a disease entity that affects many aspects of life, but is often overlooked and underdiagnosed. OSA is defined as episodes of apnea-hypopnea that disturbs not only sleep, but also daytime functioning. Symptoms can be divided into night symptoms (not breathing, snoring, gasping, fragmented sleep) and daytime symptoms (fatigue, low concentration, morning headaches, decreased libido). Moreover, OSA through many mechanisms affects the cardiovascular system and leads to its dysfunction. Purpose: The aim of this study is to draw attention to the often underdiagnosed disease entity, which is OSA, which, if left untreated, may lead to serious complications. Material and methods: In 2022, the PubMed and Google Scholar databases were searched using the following keywords: OSA, apnea, cardiovascular disorders, arrhythmias and heart disease. Works in English with the most recent data have been selected. Summary: OSA is strongly associated with cardiovascular disorders, moreover, in both cases, we find similar risk factors for these disorders. A correlation has been demonstrated between OSA and atrial fibrillation, hypertension, and arrhythmias. On the other hand, OSA is still underdiagnosed and more research is needed to understand the correlation between these diseases.